These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. FDA guidance on pharmacogenomics data submission. Savage DR; Nat Rev Drug Discov; 2003 Dec; 2(12):937-8. PubMed ID: 14756137 [No Abstract] [Full Text] [Related]
6. Pharmacogenomics: will the regulators approve? Hodgson J; Marshall A Nat Biotechnol; 1998 Mar; 16(3):243-6. PubMed ID: 9528002 [No Abstract] [Full Text] [Related]
7. Legal implications of pharmacogenomics regarding drug trials, drug labeling, and genetic testing for drug prescription: an international approach. Mandry T Food Drug Law J; 2004; 59(4):519-35. PubMed ID: 15875348 [TBL] [Abstract][Full Text] [Related]
8. Progress in pharmacogenomics and its promise for medicine. Blake CA; Sobel BE Exp Biol Med (Maywood); 2008 Dec; 233(12):1482-3. PubMed ID: 18849537 [TBL] [Abstract][Full Text] [Related]
9. The coming pharmacogenomics revolution: tailoring drugs to fit patients' genetic profiles. Noah L Jurimetrics; 2002; 43(1):1-28. PubMed ID: 17333591 [TBL] [Abstract][Full Text] [Related]
10. Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Lesko LJ; Woodcock J Nat Rev Drug Discov; 2004 Sep; 3(9):763-9. PubMed ID: 15340386 [TBL] [Abstract][Full Text] [Related]
11. Establishing clinical utility of pharmacogenetic tests in the post-FDAAA era. Evans BJ Clin Pharmacol Ther; 2010 Dec; 88(6):749-51. PubMed ID: 21081943 [TBL] [Abstract][Full Text] [Related]
12. Issues in bringing new drugs to the market. Tracey WR Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172 [No Abstract] [Full Text] [Related]
13. New drugs and product approvals from 2000. Taylor SE; Gage TW Tex Dent J; 2001 Nov; 118(11):1070-81. PubMed ID: 11806330 [No Abstract] [Full Text] [Related]
14. Drug companies accused of stalling tailored therapies. Sinha G Nat Med; 2006 Sep; 12(9):983. PubMed ID: 16960561 [No Abstract] [Full Text] [Related]
15. Pharmaceutical postmarket review: fact or fiction? Schanz SJ Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391 [No Abstract] [Full Text] [Related]
16. Is the drought over for pharming? Kaiser J Science; 2008 Apr; 320(5875):473-5. PubMed ID: 18436771 [No Abstract] [Full Text] [Related]
17. The federal preemption debate in pharmaceutical labeling product liability actions. Gross JM; Curry JA Tort Trial Insur Pract Law J; 2007; 43(1):35-70. PubMed ID: 18354866 [No Abstract] [Full Text] [Related]
18. Implications of pharmacogenomics for drug development. Kirk RJ; Hung JL; Horner SR; Perez JT Exp Biol Med (Maywood); 2008 Dec; 233(12):1484-97. PubMed ID: 18849536 [TBL] [Abstract][Full Text] [Related]
19. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk. Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527 [No Abstract] [Full Text] [Related]
20. Institute of Medicine's new drug safety report: implications for Canada. Cassels A CMAJ; 2006 Dec; 175(12):1515-6. PubMed ID: 17146086 [No Abstract] [Full Text] [Related] [Next] [New Search]